

From: [Dehdashti, Seameen \(Jean\)](#)
To: ["BDV \(Barbara Davies\)"](#)
Cc: [Dehdashti, Seameen \(Jean\)](#)
Subject: FDA Information Request (IR) RE: BLA 125671/0
Date: Thursday, March 22, 2018 3:57:39 PM
Attachments: [image002.png](#)
Importance: High

Good afternoon Barbara,

Reference is made to Novo Nordisk, Inc., original BLA 125671 submission, dated February 27, 2018. The FDA/CBER CDISC validation team has identified additional issues outlined below in **bold text**. Please provide a response no later than close-of-business (COB), Wednesday, March 28, 2018. Please let me know if you are not able to meet this deadline.

FDA Information Request:

Please send us a list of all clinical study sites in a tabular format to include the following information for each site:

- **Site ID or number**
- **Site name and country**
- **Principal investigator**
- **Total number of subjects treated at each site (please indicate the study protocols IDs under which subjects were treated)**
- **Number and List of serious adverse events**
- **Protocol deviations**

Please confirm receipt of my e-mail, and do not hesitate to contact me, should you have any questions and/or concerns.

Warm regards,

Jean Dehdashti, MSc, RAC
Regulatory Project Manager

Center for Biologics and Evaluation
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-9146
Seameen.Dehdashti@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.